Display options
Cite
Pedrianes-Martin PB, Martin-Rincon M, Morales-Alamo D, et al. Treatment of hypertension with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A cross-sectional study. J Clin Hypertens (Greenwich). 2021;23(12):2106-2114doi: 10.1111/jch.14392.
Pedrianes-Martin, P. B., Martin-Rincon, M., Morales-Alamo, D., Perez-Suarez, I., Perez-Valera, M., Galvan-Alvarez, V., Curtelin, D., de Pablos-Velasco, P., & Calbet, J. A. L. (2021). Treatment of hypertension with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A cross-sectional study. Journal of clinical hypertension (Greenwich, Conn.), 23(12), 2106-2114. https://doi.org/10.1111/jch.14392
Pedrianes-Martin, Pablo B, et al. "Treatment of hypertension with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A cross-sectional study." Journal of clinical hypertension (Greenwich, Conn.) vol. 23,12 (2021): 2106-2114. doi: https://doi.org/10.1111/jch.14392
Pedrianes-Martin PB, Martin-Rincon M, Morales-Alamo D, Perez-Suarez I, Perez-Valera M, Galvan-Alvarez V, Curtelin D, de Pablos-Velasco P, Calbet JAL. Treatment of hypertension with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A cross-sectional study. J Clin Hypertens (Greenwich). 2021 Dec;23(12):2106-2114. doi: 10.1111/jch.14392. Epub 2021 Nov 30. PMID: 34846787; PMCID: PMC8696230.
Copy Download .nbib Format: NLM
Share it on

J Clin Hypertens (Greenwich). 2021 Dec;23(12):2106-2114. doi: 10.1111/jch.14392. Epub 2021 Nov 30.

Treatment of hypertension with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A cross-sectional study.

Journal of clinical hypertension (Greenwich, Conn.)

Pablo B Pedrianes-Martin, Marcos Martin-Rincon, David Morales-Alamo, Ismael Perez-Suarez, Mario Perez-Valera, Victor Galvan-Alvarez, David Curtelin, Pedro de Pablos-Velasco, Jose A L Calbet

Affiliations

  1. Department of Endocrinology and Nutrition, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.
  2. Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Canary Islands, Spain.
  3. Department of Physical Education, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Canary Islands, Spain.
  4. Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway.

PMID: 34846787 PMCID: PMC8696230 DOI: 10.1111/jch.14392

Abstract

Hypertension in obese and overweight patients is associated with an elevated resting metabolic rate (RMR). The aim of this study was to determine whether RMR is reduced in hypertensive patients treated with angiotensin-converting enzyme inhibitors (ACEI) and blockers (ARB). The RMR was determined by indirect calorimetry in 174 volunteers; 93 (46.5 %) were hypertensive, of which 16 men and 13 women were treated with ACEI/ARB, while 30 men and 19 women with untreated hypertension served as a control group. Treated and untreated hypertensives had similar age, BMI, physical activity, and cardiorespiratory fitness. The RMR normalized to the lean body mass (LBM) was 15% higher in the untreated than ACEI/ARB-treated hypertensive women (p = .003). After accounting for LBM, whole-body fat mass, age, the double product (heart rate x systolic blood pressure), and the distance walked per day, the RMR was 2.9% lower in the patients taking ACEI/ARB (p = .26, treatment x sex interaction p = .005). LBM, age, and the double product explained 78% of the variability in RMR (R

© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.

Keywords: angiotensin; exercise; obesity; overweight; resting energy expenditure; women

References

  1. J Clin Invest. 1991 Jun;87(6):2246-52 - PubMed
  2. Hypertension. 1991 Dec;18(6):783-9 - PubMed
  3. Am J Physiol Endocrinol Metab. 2001 May;280(5):E740-4 - PubMed
  4. Circ Res. 2015 Mar 13;116(6):960-75 - PubMed
  5. Scand J Med Sci Sports. 2019 Oct;29(10):1473-1488 - PubMed
  6. Am J Physiol. 1992 Jun;262(6 Pt 1):E763-78 - PubMed
  7. Biol Sex Differ. 2019 Jul 1;10(1):31 - PubMed
  8. Metabolism. 2009 May;58(5):708-13 - PubMed
  9. Am J Physiol Regul Integr Comp Physiol. 2020 Sep 1;319(3):R288-R295 - PubMed
  10. FEBS Lett. 1992 Feb 24;298(2-3):257-60 - PubMed
  11. Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1392-9 - PubMed
  12. Hypertension. 2007 Jan;49(1):27-33 - PubMed
  13. J Clin Med. 2020 Jan 11;9(1): - PubMed
  14. Can J Sport Sci. 1991 Mar;16(1):23-9 - PubMed
  15. J Clin Invest. 2017 Apr 3;127(4):1414-1424 - PubMed
  16. Am J Clin Nutr. 1990 Feb;51(2):241-7 - PubMed
  17. BMC Cardiovasc Disord. 2018 Jan 10;18(1):4 - PubMed
  18. J Am Heart Assoc. 2017 Nov 18;6(11): - PubMed
  19. J Clin Invest. 1994 Jun;93(6):2365-71 - PubMed
  20. Hypertension. 2000 Jul;36(1):26-32 - PubMed
  21. Front Physiol. 2017 Jul 24;8:483 - PubMed
  22. Am J Clin Nutr. 2005 Nov;82(5):941-8 - PubMed
  23. J Clin Hypertens (Greenwich). 2021 Dec;23(12):2106-2114 - PubMed
  24. Am J Clin Nutr. 1983 Apr;37(4):595-602 - PubMed
  25. J Hypertens. 2004 Dec;22(12):2363-9 - PubMed
  26. Scand J Med Sci Sports. 2021 Jul;31(7):1461-1470 - PubMed
  27. Br J Nutr. 2001 Dec;86(6):641-6 - PubMed
  28. Curr Opin Nephrol Hypertens. 2019 Mar;28(2):120-127 - PubMed
  29. J Clin Invest. 2000 Jul;106(1):103-6 - PubMed
  30. Physiol Rev. 2006 Apr;86(2):435-64 - PubMed
  31. J Biol Chem. 1992 May 15;267(14):9455-8 - PubMed
  32. FASEB J. 2020 Sep;34(9):11337-11346 - PubMed
  33. Clin Exp Hypertens. 1998 May;20(4):403-16 - PubMed
  34. Ann N Y Acad Sci. 2019 Oct;1454(1):31-41 - PubMed
  35. Hypertension. 2005 Jan;45(1):142-61 - PubMed
  36. Hypertension. 2009 Mar;53(3):516-23 - PubMed
  37. J Gerontol A Biol Sci Med Sci. 2016 Jul;71(7):941-6 - PubMed
  38. Diabetologia. 2020 Mar;63(3):453-461 - PubMed

Publication Types

Grant support